An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Trial Status: active
The purpose of this study is to determine the safety and efficacy of PF-07220060 with
letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib
with letrozole) in people with breast cancer:
- HR-positive (breast cancer cells that need estrogen or progesterone to grow)
- HER2-negative (cells that have a small amount or none of a protein called HER2 on
their surface);
- locally advanced (that has spread from where it started to nearby tissue or lymph
nodes) or metastatic disease (the spread of cancer to other places in the body)
- who have not received any prior systemic anti-cancer treatment for
advanced/metastatic disease.
Approximately half of the participants will receive PF-07220060 plus letrozole while the
other half of participants will receive the investigator's choice of treatment plus
letrozole.
The study team will monitor how each participant is doing with the study treatment during
regular visits at the study clinic.
Inclusion Criteria
Histological confirmation of breast cancer with evidence of locally advanced or metastatic disease, which is not amenable to surgical resection or radiation therapy with curative intent.
